Trial · NCT00066365
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Status of FAS Ligand in Pre-chemotherapy Sample | 29 days after start of protocol therapy | Patients who were enrolled in the unilateral recurrence group do not contribute to the assessment of any Pre Chemotherapy analysis. Such patients only had tissue for assessment after the first thoracotomy which was planned for 22 days after the start of sargramostim treatment. 14 patients were evaluated for this primary outcome measure. | participants | NUMBER |
| PRIMARY | Presence of FAS in Pre-chemotherapy Sample | 29 days after start of protocol therapy | Patients who were enrolled in Group 1 (unilateral recurrence) do not contribute to the assessment of any Pre Chemotherapy analysis. Such patients only had tissue for assessment after the first thoracotomy which was planned for 22 days after the start of sargramostim treatment. | participants | NUMBER |
| PRIMARY | FAS Ligand in Post Chemotherapy Sample | 29 days after start of protocol therapy | 22 patients from the unilateral recurrence group and 13 patients from the bilateral recurrence group were evaluated for this outcome measure. | participants | NUMBER |
| PRIMARY | FAS Status in Post Chemotherapy Sample | 29 days after start of protocol therapy | 22 patients from the unilateral recurrence group and 13 patients from the bilateral recurrence group were evaluated for this outcome measure. | participants | NUMBER |
| PRIMARY | CD1a Status in Pre Chemotherapy Sample | 29 days after start of protocol therapy | Patients enrolled in the unilateral recurrence group do not contribute to the assessment of any Pre Chemotherapy analysis. Such patients only had tissue for assessment after the first thoracotomy which was planned for 22 days after the start of sargramostim treatment. 7 patients were evaluated from the bilateral recurrence group. | participants | NUMBER |
| PRIMARY | CD1a Status in Post Chemotherapy Sample | 29 days after start of protocol therapy | 20 patients were evaluated for this outcome measure from the unilateral group and 7 patients were evaluated from the bilateral group. | participants | NUMBER |
| PRIMARY | S100 Status in Pre Chemotherapy Sample | 29 days after start of protocol therapy | Patients enrolled in the unilateral recurrence group do not contribute to the assessment of any Pre Chemotherapy analysis. Such patients only had tissue for assessment after the first thoracotomy which was planned for 22 days after the start of sargramostim treatment. 7 patients were evaluated from the bilateral recurrence group. | participants | NUMBER |
| PRIMARY | S100 Status in Post Chemotherapy Sample | 29 days after start of protocol therapy | 20 patients from the unilateral recurrence group and 10 patients from the bilateral recurrence group were evaluated for this outcome measure. | participants | NUMBER |
| PRIMARY | Clusterin Status in Pre Chemotherapy Sample | 29 days after start of protocol therapy | Patients enrolled in the unilateral recurrence group do not contribute to the assessment of any Pre Chemotherapy analysis. Such patients only had tissue for assessment after the first thoracotomy which was planned for 22 days after the start of sargramostim treatment. 7 patients were measured from the bilateral recurrence group. | participants | NUMBER |
| PRIMARY | Clusterin Status in Post Chemotherapy Sample | 29 days after start of protocol therapy | This outcome measure was evaluated in 30 patients, 20 patients in the unilateral recurrence group and 10 patients in bilateral recurrence group. | participants | NUMBER |
| PRIMARY | Event Free Survival (EFS) | Time of enrollment to Event or 5 years from enrollment, whichever occurs first | There were 4 ineligible unilateral patients and 2 ineligible bilateral patients not included in this analysis. | years | MEDIAN |
| PRIMARY | Feasibility Success | Enrollment through 21 days of protocol therapy | This outcome measure was calculated for eligible patients only. This yields 27 patients for assessment of this measure in Group 1 and 16 patients for assessment of this measure in Group 2. | participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00066365/outcomes